Cancer cells surviving cisplatin chemotherapy increase stress-induced OMA1 activity and mitochondrial fragmentation
Cancer is one of the leading causes of deaths worldwide. Once cancer cells acquire therapy resistance, they become the main driver of cancer lethality in patients. Thus, mechanisms of therapy resistance must be investigated to improve patient outcomes. Mitochondria are critical organelles in the cellular stress responses, undergoing dynamic morphological and functional changes in response to external stimuli. We and others have identified a chemotherapy-resistant cancer cell state where cells that survive treatment exhibit a dramatic increase in cell size and remain non-proliferative for weeks. In this study, we demonstrate that cancer cells that enter this resistant cell state in response to cisplatin increase OMA1 activity and decrease mitochondrial fusion and function to combat oxidative stress. These findings contribute to further understanding the role of the mitochondrial stress responses in therapy resistance in cancer and provide a potential therapeutic avenue to targeting cancer cells that enter this chemotherapy-resistant cell state.
Authors
- Sarah R. Amend (ORCID: https://orcid.org/0000-0002-5606-1262)
- Qin Ni (ORCID: https://orcid.org/0000-0002-0738-1817)
- Zhuoxu Ge
- Kenneth J. Pienta (ORCID: https://orcid.org/0000-0002-4138-2186)
- Sean X. Sun
- Chenille A McCullum
- Melvin Li
- Louis T. A. Rolle
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- NanoBio (United States) (US)
- Johns Hopkins Hospital (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1038/s41598-025-33677-1
- Primary Topic
- Mitochondrial Function and Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences
- Congressionally Directed Medical Research Programs
- DOD Prostate Cancer Research Program